183,066 Shares of ANI Pharmaceuticals, Inc. $ANIP Acquired by Bank of America Corp DE

Key Points

• Bank of America acquired 183,066 shares of ANI Pharmaceuticals in the second quarter, worth approximately $15.2 million and representing a 0.8% stake. Institutional investors collectively own 76.05% of the company.
• ANI Pharmaceuticals exceeded quarterly expectations, reporting $2.21 in EPS on $266.04 million in revenue, with revenue rising 25.8% year over year. The company provided fiscal 2026 EPS guidance of $9.19–$9.69.
• Shares opened at $74, near the lower end of their 12-month range, while analyst sentiment remained cautious: the stock carries an average “Hold” rating and a consensus price target of $98.00. Company insiders sold $2.18 million of shares in the last quarter.

Bank of America Corp DE bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 183,066 shares of the specialty pharmaceutical company's stock, valued at approximately $15,154,000. Bank of America Corp DE owned 0.80% of ANI Pharmaceuticals as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of ANIP. Arrowstreet Capital Limited Partnership increased its position in shares of ANI Pharmaceuticals by 19.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company's stock valued at $43,399,000 after buying an additional 91,153 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of ANI Pharmaceuticals by 8.9% during the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company's stock worth $40,843,000 after purchasing an additional 43,523 shares in the last quarter. Ranger Investment Management L.P. bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth $28,406,000. Deutsche Bank AG purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at $26,775,000. Finally, William Blair Investment Management LLC purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at $21,372,000. Institutional investors own 76.05% of the company's stock.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 5,400 shares of the company's stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $71.00, for a total transaction of $383,400.00. Following the completion of the transaction, the chief executive officer owned 339,089 shares in the company, valued at approximately $24,075,319. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $72.80, for a total value of $207,480.00. Following the completion of the sale, the chief financial officer directly owned 171,843 shares in the company, valued at approximately $12,510,170.40. The trade was a 1.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 28,325 shares of company stock valued at $2,177,695 in the last quarter. Insiders own 8.10% of the company's stock.

ANI Pharmaceuticals Stock Down 0.1%

Shares of ANI Pharmaceuticals stock opened at $74.00 on Friday. ANI Pharmaceuticals, Inc. has a twelve month low of $69.58 and a twelve month high of $97.00. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The company's 50 day moving average is $75.69 and its 200 day moving average is $78.12. The company has a market cap of $1.70 billion, a price-to-earnings ratio of 15.95, a price-to-earnings-growth ratio of 2.36 and a beta of 0.45.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping analysts' consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm's revenue was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Analyst Ratings Changes

ANIP has been the topic of a number of recent research reports. Canaccord Genuity Group reduced their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a research report on Monday, August 10th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Wall Street Zen cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Guggenheim reduced their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a report on Monday, August 10th. Finally, Oppenheimer began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday. They issued a "market perform" rating and a $85.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals currently has an average rating of "Hold" and an average price target of $98.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI's portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.